Refine by
Medical Reporting Articles & Analysis
56 news found
“For too long, Neurosurgeons treating hydrocephalus, as well as patients and caregivers, have been requesting a noninvasive, simple solution to help keep implanted shunts flowing,” reported Anuncia Medical CEO Elsa Chi Abruzzo. “The ReFlow can be implanted in minutes along with the neurosurgeon’s preferred shunt type to empower patients ...
Boston: “According to the latest BCC Research study, the demand for Medical Kiosks: Global Market and Forecasts is estimated to increase from $1.4 billion in 2022 to reach $3.2 billion by 2028, at a compound annual growth rate (CAGR) of 14.8% from 2022 through 2028.” The comprehensive report on the medical kiosks market delivers a ...
Cheshier from the University of Utah Health and Intermountain Primary Children’s Hospital, reported “Neurosurgeons treating hydrocephalus have been waiting too long for a non-surgical option to help keep implanted shunts flowing. ...
Medical Technology Innovation’ report). ** The product was developed in just 12 months rather than the industry standard average of 31 months (also quoted in the report). *** Field Orthopaedics CEO Dr Chris Jeffery, 31, said the initial response to the product in the USA was overwhelming and proved that Australian products were not just ...
This enables clinicians to identify stable patients that may be candidates for early discharge, potentially reducing hospital stays while providing medical grade monitoring in the convenience and comfort of a patient’s home. ...
Food and Drug Administration (FDA), the Company is allowed to apply for a limited clinical investigation known as an Early Feasibility Study (EFS), which is designed for novel technologies such as the SCS. About Microbot Medical Microbot Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational ...
Ended the quarter with $47.2 million in cash and investments – expected to fund operations through the end of 2024, including release of topline SAVVE pivotal trial data IRVINE, CA / August 3, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) (“enVVeno” or the “Company”), a company setting new standards of care for the treatment of venous disease, ...
TORONTO, June 09, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced the voting results form the company’s Annual and Special Meeting of its shareholders held on ...
TORONTO--(BUSINESS WIRE)-- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced financial results for the three months ended March 31, 2022. ...
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today reported financial results for its first quarter ended March 31, 2022. Financial Highlights and Recent ...
Ended the quarter with $51.3 million in cash – expected to fund operations through the end of 2024 including release of topline pivotal trial data Ongoing advancement of SAVVE U.S pivotal trial with 20 sites available to enroll patients Progress on development of second device for the treatment of venous disease expected to be unveiled in mid-2022 IRVINE, CA / May 2, 2022 / enVVeno ...
Ended the Year With $55 Million in Cash Expected To Fund Operations Through the End of 2024 Including Release of Topline Pivotal Trial Data Nine (9) VenoValve Surgeries Successfully Completed and 16 Clinical Sites Currently Active in Ongoing SAVVE U.S Pivotal Trial Continued Advancement in Development of Second Device for the Treatment of Venous Disease Expected To Be Unveiled in Mid-2022 ...
HINGHAM, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- The operational momentum that Microbot Medical Inc. (Nasdaq: MBOT) experienced at the end of 2021 has continued well into the 2022 first quarter. ...
Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2021. ...
Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the fourth quarter and full year of 2021 after the close of trading on Wednesday, February 16, 2022. On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern ...
Current estimations suggest 2.4 million operations will have been cancelled by 2021 year-end, and a report by the British Medical Association forecasts that by 2043, medical workforce shortages could be up to over 80,000 doctors. ...
In addition, 47% of respondents who experienced side effects of antipsychotic medication said that they had often or sometimes taken medication to manage such side effects. ...
ByAlkermes
In Nature Communications (15 Dec 2021), lead author Yu-Ting Yen and colleagues at the China Medical University and Hospital, Taichung, Taiwan reported that treatment with LB-100 is associated with new antigen production, tumor infiltration of cytotoxic T cells, and enhanced responsiveness to immune checkpoint blockade in mouse models of colorectal, ...
Fierce Pharma has a broad coverage, tracking both the tiny, virtual start-ups and Big Pharma, key medical meetings and special reports that shed new light on the industry. ...
Even a slight loss of vision can create a cascade of medical costs, from added glaucoma medications, surgeries, and doctor visits to additional hospitalizations from fractures and falls, to lost productivity at work. ...